Jade Biosciences, Inc.JBIO stock score: 36/100
$15.06 · -2.78% · Scored Nov 19, 2026
- Technical
- 38
- Fundamental
- 36
- News
- 49
The reading
Jade Biosciences (JBIO) scores 36 out of 100, which reads bearish, higher than 14% of Healthcare stocks and 15% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 36, technicals 38.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Quality (Yearly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 42 and contrarian oscillators 50.
News sentiment is neutral at 49; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 30 to 45, and it is down 7 points over the period.
About Jade Biosciences
Jade Biosciences (JBIO) is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. Its lead candidate is an antibody that targets APRIL, a protein that drives production of immunoglobulin A, and is being developed for IgA nephropathy, a chronic kidney disease in which abnormal IgA deposits damage the kidneys. Early data in healthy volunteers showed deep, lasting IgA reductions after a single dose, and the drug has moved into a mid-stage trial in patients. The pipeline also includes an antibody against the BAFF receptor intended for autoimmune diseases such as rheumatoid arthritis, along with an earlier program. The company has no product revenue and funds its research with cash raised from investors.
In IgA nephropathy, Jade faces competition from Otsuka, Vera Therapeutics, Vertex and Novartis, which have approved or late-stage drugs for the disease, along with established kidney treatments. Its edge rests on an antibody engineered for a long half-life, which could allow dosing every few months, and on a focused pipeline aimed at immune targets with validated biology. Investors who follow JBIO stock tend to watch data from the mid-stage IgA nephropathy trial and plans for a pivotal study. Early trials of its other candidates are closely followed. Cash runway, competitors’ clinical and regulatory progress, and any partnership deals are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward JBIO’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
36Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
How reliably yearly earnings grow: the share of years with higher earnings, the compound growth rate, how steady that growth is, and the last two yearly changes.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
41Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Know Sure Thing (KST) combines multiple rate-of-change calculations to identify long-term trend reversals.
Where the close sits against its 50-day SMA.
Holding it back
Where the close sits against its 100-day SMA.
Where the close sits against its 200-day SMA.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 49
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 37 | 1 |
| Daily | 41 | 3 |
| Weekly | 27 | 2 |
| Monthly | 45 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 36 |
| Nov 18, 2026 | 37 |
| Nov 17, 2026 | 37 |
| Nov 16, 2026 | 37 |
| Nov 15, 2026 | 38 |
| Nov 14, 2026 | 38 |
| Nov 13, 2026 | 32 |
| Nov 12, 2026 | 30 |
| Nov 11, 2026 | 41 |
| Nov 10, 2026 | 41 |
| Nov 8, 2026 | 36 |
| Nov 7, 2026 | 36 |
| Nov 6, 2026 | 38 |
| Nov 5, 2026 | 36 |
| Nov 4, 2026 | 39 |
| Nov 3, 2026 | 38 |
| Nov 2, 2026 | 36 |
| Nov 1, 2026 | 36 |
| Oct 30, 2026 | 35 |
| Oct 29, 2026 | 37 |
| Oct 28, 2026 | 36 |
| Oct 27, 2026 | 38 |
| Oct 26, 2026 | 35 |
| Oct 25, 2026 | 37 |
| Oct 24, 2026 | 36 |
| Oct 23, 2026 | 35 |
| Oct 22, 2026 | 38 |
| Oct 21, 2026 | 39 |
| Oct 20, 2026 | 37 |
| Oct 19, 2026 | 35 |
| Oct 18, 2026 | 34 |
| Oct 17, 2026 | 34 |
| Oct 16, 2026 | 35 |
| Oct 15, 2026 | 34 |
| Oct 14, 2026 | 34 |
| Oct 13, 2026 | 34 |
| Oct 12, 2026 | 36 |
| Oct 11, 2026 | 37 |
| Oct 10, 2026 | 37 |
| Oct 9, 2026 | 37 |
| Oct 8, 2026 | 36 |
| Oct 7, 2026 | 34 |
| Oct 6, 2026 | 34 |
| Oct 5, 2026 | 36 |
| Oct 4, 2026 | 35 |
| Oct 3, 2026 | 35 |
| Oct 2, 2026 | 36 |
| Oct 1, 2026 | 34 |
| Sep 30, 2026 | 34 |
| Sep 29, 2026 | 34 |
| Sep 28, 2026 | 34 |
| Sep 27, 2026 | 34 |
| Sep 26, 2026 | 34 |
| Sep 25, 2026 | 34 |
| Sep 24, 2026 | 35 |
| Sep 23, 2026 | 35 |
| Sep 22, 2026 | 36 |
| Sep 21, 2026 | 36 |
| Sep 20, 2026 | 35 |
| Sep 19, 2026 | 35 |
| Sep 18, 2026 | 36 |
| Sep 17, 2026 | 36 |
| Sep 16, 2026 | 34 |
| Sep 15, 2026 | 34 |
| Sep 14, 2026 | 37 |
| Sep 13, 2026 | 37 |
| Sep 12, 2026 | 37 |
| Sep 11, 2026 | 37 |
| Sep 10, 2026 | 38 |
| Sep 9, 2026 | 39 |
| Sep 8, 2026 | 40 |
| Sep 7, 2026 | 40 |
| Sep 6, 2026 | 40 |
| Sep 5, 2026 | 40 |
| Sep 4, 2026 | 39 |
| Sep 3, 2026 | 40 |
| Sep 2, 2026 | 45 |
| Sep 1, 2026 | 42 |
| Aug 31, 2026 | 43 |
| Aug 30, 2026 | 41 |
| Aug 29, 2026 | 42 |
| Aug 28, 2026 | 41 |
| Aug 27, 2026 | 42 |
| Aug 26, 2026 | 43 |
| Aug 25, 2026 | 45 |
| Aug 24, 2026 | 43 |
| Aug 23, 2026 | 43 |
| Aug 22, 2026 | 43 |
Key facts
- Market cap
- $1.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- —
- Risk grade (1–10)
- 9
- Next earnings
- Nov 13, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| VOR Vor Biopharma | $1.1B | 43 |
| NKTR Nektar Therapeutics | $1.1B | 27 |
| INBX Inhibrx Biosciences | $1.1B | 38 |
| ANRO Alto Neuroscience | $1.1B | 36 |
| DRTS Alpha Tau Medical | $1.0B | 30 |
| OMER Omeros | $1.0B | 57 |
Questions
What is JBIO's stock rating today?
JBIO scores 36/100 (Bearish) as of Nov 19, 2026: technical 38, fundamental 36, and news sentiment 49, which is shown but not counted. Scores are recomputed every night.
What does Jade Biosciences do?
Jade Biosciences (JBIO) is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. Its lead candidate is an antibody that targets APRIL, a protein that drives production of immunoglobulin A, and is being developed for IgA nephropathy, a chronic kidney disease in which abnormal IgA deposits damage the kidneys.
Is JBIO stock a buy?
The score is not a buy or sell recommendation. A 36 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the JBIO score calculated?
88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/jbio/"><img src="https://stocksscores.com/stocks/jbio/badge.svg" alt="JBIO stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/jbio/)